Sunday, July 12, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 341
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

341 results for “Novartis” Back to intelligence hub

Search results

Page 6 of 15
  1. Ribociclib

    Novartis Pharmaceuticals

    Advanced, Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial
  2. Ribociclib

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  3. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial
  4. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial
  5. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial
  6. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  7. Secukinumab

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    2 trials
  8. Secukinumab

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial
  9. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial
  10. TQJ230

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial
  11. Telbivudine

    Novartis Pharmaceuticals

    Hepatitis

    phase 3 small molecule completed

    1 trial
  12. VAY736

    Novartis Pharmaceuticals

    Sjogren Syndrome

    phase 3 mab active

    1 trial
  13. VAY736F12301E1

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial
  14. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  15. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  16. Zoledronic acid

    Novartis Pharmaceuticals

    Osteoporosis

    phase 3 small molecule completed

    1 trial
  17. Zoledronic acid

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  18. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial
  19. canakinumab

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials
  20. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial
  21. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial
  22. secukinumab

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial
  23. telbivudine or lamivudine

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial
  24. zigakibart

    Novartis Pharmaceuticals

    Kidney Diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.